Stryker shares tumble despite strong Q2 results and raised guidance
IRVINE, Calif. - ReShape Lifesciences (NASDAQ:RSLS), a company specializing in weight loss and metabolic health solutions, has announced the pricing of its public stock offering. The company is offering 1,054,604 shares at $2.50 each, expecting to raise approximately $2.6 million before deducting fees and expenses associated with the placement. According to InvestingPro data, the stock has seen significant volatility, trading near its 52-week low of $4.03, with the company’s market capitalization currently standing at approximately $3.1 million.
The offering is slated to close today, with Maxim Group LLC serving as the sole placement agent. This move follows the effective shelf registration statement filed with the U.S. Securities and Exchange Commission on May 9, 2025, and declared effective on May 14, 2025. InvestingPro analysis indicates the company’s financial health score is currently rated as WEAK, with an EBITDA of -$6.28 million in the last twelve months.
ReShape Lifesciences, known for its FDA-approved Lap-Band® and Lap-Band® 2.0 Flex Systems, provides minimally invasive long-term obesity treatments. The company also offers the ReShape Diabetes Neuromodulation system, a therapeutic implant for diabetes management, and the Obalon® balloon technology for non-surgical weight loss. Despite challenging market conditions, the company maintains a healthy gross profit margin of 63.74% and holds more cash than debt on its balance sheet. For detailed analysis and additional insights, check out the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
The completion of the offering is contingent upon customary closing conditions. The final terms will be detailed in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities. The sale of these securities will not be conducted in any jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The information provided is based on a press release statement.
In other recent news, ReShape Lifesciences has achieved significant regulatory milestones by obtaining certification under the European Union Medical Device Regulation (MDR) and UK Conformity Assessment (UKCA), ensuring their medical devices meet stringent safety and quality standards in Europe and the United Kingdom. Additionally, ReShape Lifesciences has made progress in its merger with Vyome Therapeutics, as detailed in a recent SEC filing. The merger, pending Nasdaq approval, is expected to enhance the company’s product pipeline and capabilities. In another development, ReShape Lifesciences announced a 1-for-25 reverse stock split, consolidating shares to better align with market requirements. The company also revealed promising pre-clinical data for its Diabetes Neuromodulation device, which effectively manages glucose levels without causing cardiac side effects. Furthermore, ReShape Lifesciences has amended the terms of an asset purchase agreement with Ninjour Health International Limited, reducing the exercise price and extending the agreement’s termination date. These recent developments highlight ReShape Lifesciences’ strategic efforts in regulatory compliance, corporate restructuring, and product innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.